ApiJect
- Company typePrivate
- Founded2012
- HeadquartersStamford, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What ApiJect does
ApiJect is a private Delaware-incorporated medical technology company headquartered in Stamford, Connecticut, that develops a proprietary Blow-Fill-Seal (BFS) platform for aseptically manufacturing single-dose prefilled injection devices. Its core technology combines aseptically filled BFS plastic containers with a proprietary pen needle hub featuring an integrated one-way valve, producing a ready-to-use single-dose prefilled injector that, by design, cannot be reused. The platform is differentiated by a proprietary temperature-management system that allows BFS filling of heat-sensitive biologics including ultra-cold mRNA vaccines, by a four-patent U.S. IP portfolio on the modular injector system, and by a peer-reviewed 55% carbon-footprint reduction versus single-dose glass vials and 1/100th the water usage per dose.
ApiJect generates revenue through three primary mechanisms: licensing its proprietary BFS injector technology to pharmaceutical and biotech companies and to contract manufacturing organizations (CMOs/CDMOs) on multi-year negotiated enterprise contracts; selling unit-dose generic injectable medicines to U.S. hospitals through its subsidiary The Vanguard Utility's Global Pharmacy Reserve platform (300+ SKUs, launched May 2026); and providing BFS development, feasibility-filling, mold-design, prototype-testing, and training services through its Technology Development Center in the greater Orlando area and its Studio One design innovation center in London. Named end-customers are limited: Spanish pharma HIPRA Human Health for its recombinant-protein COVID-19 vaccine, and U.S. hospitals reached through Global Pharmacy Reserve. The company has signed a 30,000 sq ft manufacturing lease in Apex, North Carolina, planned to come online in 2027 as an FDA-registered 503B outsourcing facility and the headquarters of The Vanguard Utility.
The company is led by co-founders Jay Walker (Executive Chairman & CEO) and Marc Koska, OBE (Co-Founder & Head of Product Design, inventor of the K-1 auto-disable syringe), supported by senior executives drawn from West Pharmaceutical Services, Becton Dickinson, Pfizer, and GSK. It has raised approximately $156 million in disclosed capital across a $111M 2022 round led by Royalty Pharma and Jefferies, a $35M 2024 equipment financing from Trinity Capital, and grants from HHS/ASPR and the Bill & Melinda Gates Foundation, and has filed a New Drug Application with the FDA for its first BFS-based prefilled injection device.
ApiJect firmographics
Firmographics- Name
- ApiJect
- Legal name
- Apiject Systems, Corp.
- Website
- https://apiject.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
ApiJect industry classification
Industry- Product category
- Drug Delivery Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)
- akta.pro secondary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
Keywords
Where ApiJect is headquartered
LocationHeadquarters
- HQ city
- Stamford
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
ApiJect business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
Revenue model
- Platform Licensing: ApiJect licenses its proprietary BFS prefilled injector technology to pharmaceutical and biotech companies for use in their own manufacturing facilities or through contract manufacturing partners.
- Generic Injectable Drug Sales (via Vanguard Utility): Through subsidiary The Vanguard Utility, ApiJect manufactures and sells generic injectable medicines directly to U.S. hospitals via the Global Pharmacy Reserve platform, offering 300+ unit-dose generic medicines.
- Contract Manufacturing Services: Provides fill-finish manufacturing services for pharmaceutical companies using BFS technology at partner facilities and the Apex, NC manufacturing plant.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B enterprise pricing for pharmaceutical partnerships |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
ApiJect product offering
Product offeringCore offering
ApiJect develops and licenses a Blow-Fill-Seal (BFS) prefilled injection platform that combines aseptically-filled single-dose plastic BFS containers with proprietary pen needle hubs. The company provides BFS device development services through Studio One (London design center) and the ApiJect Technology Development Center (Orlando), and licenses its technology to contract manufacturing partners. Through its subsidiary The Vanguard Utility, it also manufactures and sells unit-dose generic injectable medicines directly to U.S. hospitals via the Global Pharmacy Reserve platform.
Product overview
ApiJect is a medical technology company offering the Apiject Platform — a technology platform anchored by Blow-Fill-Seal (BFS) manufacturing that combines aseptically-filled BFS plastic containers with pen needle hubs to create scalable, single-dose prefilled injection devices. The platform is supported by Studio One (a design innovation center in London), the Apiject Technology Development Center (a non-GMP development and prototype facility in the Orlando area), and associated development services including prototype testing, mold design, feasibility filling, BFS training, and Proof-of-Concept studies. The company operates through its subsidiary The Vanguard Utility, which commercializes BFS-based pharmaceutical supply via the Global Pharmacy Reserve platform for U.S. hospitals. The portfolio also includes conceptual next-generation devices such as BUBBLEJECT™.
Differentiator
Problem solved
Functional benefit
Brands
- BUBBLEJECT: Next generation pre-filled injectable device redefining drug delivery and increasing access to those who need it most
- Prefilled Apiject Injector
- Apiject Platform
Products and services
- ApiJect Platform The core BFS prefilled injector technology platform offered to pharmaceutical companies for licensing and joint device development. Combines aseptically-filled BFS plastic containers with pen needle hubs to deliver single-dose prefilled injection devices.
- BUBBLEJECT Prefilled Injector A next-generation prefilled injectable device concept featuring a one-way valve integrated into a soft LDPE BFS container. When the needle hub is twisted, the valve tears to open the container for dose delivery.
- Studio One ApiJect's design innovation center in London where device designers and engineers create BFS-based prefilled drug delivery systems for pharmaceutical partners across various injection environments and dose sizes.
- ApiJect Technology Development Center A 15,000+ sq ft non-GMP development center in the greater Orlando area providing prototype manufacturing and prefilled device development, including drug product compatibility testing, prototype BFS mold design, feasibility filling, and commercial mold design and maintenance.
- BFS Training & Partnerships BFS training and partnership services provided at the ApiJect Technology Development Center, helping pharma and CMO partners' engineers gain the knowledge and skills to operate BFS manufacturing lines.
- Test Drive Our Technology (Proof-of-Concept) Feasibility and proof-of-concept services that use as little as 8 liters of vaccine or drug product to test compatibility in BFS using ApiJect prefilled injector technology, enabling companies to test-drive the platform.
- Feasibility Filling In-house BFS filling services for device development at the ApiJect Technology Development Center, including prototype and commercial mold design, shuttle and rotary BFS machines, and proprietary temperature management for filling drug products including ultra-cold vaccines.
- Mold Design World-class BFS mold design and manufacturing services with more than 50 combined years of combined experience, including 3D mold design, CMC machines, mold repair, and quality inspection for shuttle and rotary BFS machines.
- The Vanguard Utility An independent company spun off from ApiJect focused on commercializing Blow-Fill-Seal for liquid pharmaceuticals. It procures or develops generic liquid pharmaceuticals, packages them using BFS, and sells them directly to hospitals under FDA 503B regulations.
- Global Pharmacy Reserve (GPR) A unit-dose medicines platform under The Vanguard Utility, offering more than 300 generic medicines to U.S. hospitals, sourced from a pharmaceutical repackaging and distribution partner, now operational with shipments beginning May 1, 2026.
Quantifiable outcome
- 55% smaller carbon footprint compared to single-dose glass vials
- +5 more outcomes
Companies that use ApiJect
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
ApiJect technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ApiJect partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, major, strategic and minor.
- Tae-Chang Industrial (T-C)coreSouth Korean manufacturer of needle products and blood bags serving as key manufacturing partner for ApiJect Needle Hub components. T-C is a key R&D contributor on the Needle Hub design and a Board Member of ApiJect through CEO Hanjin In.
- Global Pharmaceutical Repackaging and Distribution PartnermajorEstablished pharmaceutical repackaging and distribution partnership for sourcing, quality assurance, and distribution of FDA-approved unit-dose medicines through Global Pharmacy Reserve platform serving U.S. hospitals.
- HIPRA Human HealthstrategicHIPRA has explored partnership with ApiJect to combine their recombinant protein COVID-19 vaccine with ApiJect's BFS fill-finish technology, citing benefits to supply chain, global access, and environmental footprint.
- World-Class CMO/CDMO PartnerscoreApiJect works with contract manufacturing organizations to license its proprietary BFS technology for fill-finish production of prefilled injection devices. Manufacturing partner in South Carolina has capacity for 540 million units annually.
- Butterfly WorksminorSocial innovation organization conducting field research in Kenya (Kwale county) on intradermal injections and injectable contraceptives as part of ApiLabs Field Research Network to inform device design for global health markets.
- Dalberg DesignminorGlobal design and strategy consultancy conducting AFRN field research in India (Bihar and Karnataka states) to gather user feedback on medical devices for ApiLabs/ApiJect global health product development.
Scale indicators14 records
Recent moves9 records
Expansion highlights6 records
ApiJect competitors and assessment
Company assessmentBroad incumbents
- Becton, Dickinson and Company: Global medical device leader with a large Pharmaceutical Systems segment that manufactures prefilled syringes, auto-injectors, and drug delivery devices used by virtually every major pharma company. Directly comparable to ApiJect's prefilled injector ambitions and significantly larger scale with established FDA-cleared products.
- West Pharmaceutical Services: Leading supplier of elastomeric components, containment systems, and delivery devices for injectable drugs, including prefilled syringe components and auto-injector platforms. Several ApiJect senior leaders (COO, VP Device Development, VP Packaging) previously worked at West, making it a closely comparable technology and competitor.
- Gerresheimer: European-headquartered manufacturer of pharmaceutical glass and plastic containers including prefilled syringes, vials, and ampoules. Competes with ApiJect for primary packaging of injectable drugs and offers comparable pharma-quality manufacturing at scale.
- Schott Pharma: Manufacturer of high-quality pharmaceutical glass and polymer containers, including prefilled syringes and vials used in injectable drug delivery. Competitor in primary container space with deep pharma customer relationships and global scale.
- Catalent: Major CDMO offering injectable fill-finish services and drug delivery solutions including prefilled syringe manufacturing. Broader service portfolio but competes for the same pharmaceutical outsourcing spend on fill-finish for injectable medicines.
Direct peers
- Stevanato Group: Italian-based provider of drug containment and delivery solutions including prefilled syringes, vials, and integrated device platforms for pharma customers. Direct competitor in the prefilled injector market with established FDA-cleared products and global manufacturing footprint.
- Unither Pharmaceuticals: BFS-focused contract manufacturer and developer of sterile single-dose unit-dose pharmaceutical products, particularly in ophthalmic and respiratory applications. Most direct BFS peer to ApiJect with comparable Blow-Fill-Seal aseptic fill-finish capability; an ApiJect VP previously worked at Unither.
- Nephron Pharmaceuticals: South Carolina-based BFS manufacturer of generic respiratory and injectable drugs at large scale. Multiple ApiJect leaders previously held senior roles at Nephron, and it represents a direct competitor in BFS-based injectable manufacturing and 503B outsourcing.
- Rommelag: German manufacturer of BFS machinery and CMO services, the original equipment maker behind most BFS aseptic fill-finish lines. Directly comparable as the underlying technology and service provider that ApiJect's platform builds upon and competes with in CMO services.
Emerging players
- Recipharm: European CDMO with injectable fill-finish capabilities including BFS manufacturing and prefilled syringe services. Comparable contract manufacturing model targeting pharma customers seeking outsourced sterile injectable production.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ApiJect social profiles
Digital presenceApiJect financial estimates
Financial estimateRevenue estimate
Valuation estimate
ApiJect leadership team
Management profileNumber of profiles
Profiles16 records
ApiJect subsidiaries and ownership
Company hierarchySubsidiaries3 records
ApiJect funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ApiJect M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ApiJect
What does ApiJect do?
ApiJect develops and licenses a Blow-Fill-Seal (BFS) prefilled injection platform that combines aseptically-filled single-dose plastic BFS containers with proprietary pen needle hubs. The company provides BFS device development services through Studio One (London design center) and the ApiJect Technology Development Center (Orlando), and licenses its technology to contract manufacturing partners. Through its subsidiary The Vanguard Utility, it also manufactures and sells unit-dose generic injectable medicines directly to U.S. hospitals via the Global Pharmacy Reserve platform.
Is ApiJect a public or private company?
ApiJect is a private company. It is classified as venture growth investor backed and is currently operating.
When was ApiJect founded?
ApiJect was founded in 2012. It employs 51 to 100 people.
Where is ApiJect based?
ApiJect is headquartered in Stamford, United States, in the North America region.
How does ApiJect make money?
Three revenue lines are on record. Platform Licensing is the primary driver. The others are generic Injectable Drug Sales (via Vanguard Utility) and contract Manufacturing Services.
Who are ApiJect's main competitors?
Broad incumbents on record are Becton, Dickinson and Company, West Pharmaceutical Services, Gerresheimer, Schott Pharma and Catalent. Direct peers are Stevanato Group, Unither Pharmaceuticals, Nephron Pharmaceuticals and Rommelag. Recipharm is listed as an emerging player.
Does ApiJect have an API?
No public API is recorded for ApiJect.
What industry is ApiJect in?
ApiJect's product category is Drug Delivery Devices. Its primary akta.pro industry code is HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens), with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 339113 and its SIC code is 3841.